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L E T T E R  T O  T H E  E D I T O R
The first report of hemoglobin E in combination with the highly 
unstable alpha‐globin variant Hb Adana: The importance of 
molecular confirmation
HbE is a common hemoglobin variant causing only minimal red cell 
abnormalities in carriers. Alpha‐globin gene defects may cause de‐
creased MCV and reduction of the percentage of HbE.1 Molecular 
analysis involves gap‐PCR for the most common alpha‐thalassemia 
rearrangements and covers over 80% of all alpha‐thalassemia de‐
fects. Less frequently point mutations or unknown deletions are 
involved, which can be detected by Sanger sequencing and MLPA. 
Sometimes, the combination of HbE and alpha‐thalassemia may go 
undetected if molecular analysis is not standardly performed, es‐
pecially if the HPLC does not show a reduced percentage of HbE. 
Depending on the type of Hb variant or alpha‐thalassemia defect, 
this could have serious consequences for counseling. Hb Adana 
F I G U R E  1   A, Capillary electrophoresis results showed 76% HbA, 3% HbA2, 0 and 20.2% HbE. B, High‐performance liquid 
chromatography results showed 59.1% HbA, 3.7% HbA2, 0.2% HbF, and 25.8% HbE. The HbE and HbA2 peaks were not completely 
separated in HPLC which could explain the slight overestimation of the HbE level in our patient. With CE, the HbE level was slightly 
decreased compared to HPLC and to the literature for a plain HbE carrier. No HbH or Hb Bart's have been shown in the two graphs [Colour 
figure can be viewed at wileyonlinelibrary.com]
(A) (B)
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(c.179G>A), a highly unstable alpha‐globin gene variant, interacts 
with deletional and nondeletional mutations to produce HbH disor‐
ders with varying clinical manifestations from asymptomatic to se‐
vere anemia with significant hepatosplenomegaly. The most severe 
form of HbH disorders is the HbH hydrops fetalis, where the fetus 
usually dies in utero or shortly after birth due to a severe intrauter‐
ine hemolytic anemia.2 Here, we report, to our knowledge, the first 
case of a carrier of HbE (c.79G>A p.Glu27Lys) and the highly unsta‐
ble Hb Adana variant (HbA2: c.179G>A p.Gly60Asp). We present a 
case of a 53‐year‐old man with normal MCV, a slightly decreased 
MCH without anemia. Biochemical assays showed a borderline de‐
creased percentage of HbE in capillary electrophoresis (CE) but nor‐
mal HbE levels in high‐performance liquid chromatography (HPLC) 
which could easily have been mistaken for a regular HbE carrier. Hb 
Adana was detected by alpha‐globin gene sequencing following a 
negative gap‐PCR result for the seven most common alpha‐thalas‐
semia deletions.
The complete blood count (CBC) (Horiba medical, ABX Micros 
ES60) showed normocytic hypochromic parameters without anemia 
(Hb = 14.1 g/dL, MCV = 83 fl, MCH = 25.1 pg), Zinc protoporphyrin 
(ZPP) (AVIV Hematofluorometer Model 206) was normal (ZPP = 47), 
CE (Sebia) and HPLC (Trinity Biotech Premier Hb9210™) showed a 
low level of HbE (20.2% and 25.8%, respectively) (Figure 1; Table 1). 
Direct sequencing of the HBB gene (ABI PRISM™ 3730 DNA se‐
quencer) confirmed the presence of the βE mutation (HBB:c.79G>A 
p.Glu27Lys). Normally Hb E carriers without iron deficiency show 
HbE levels between 25% and 30%.1 The HPLC result showed 25.8% 
HbE, which is concordant with a HbE carrier. However, the HbE per‐
centage on CE was slightly decreased (20.2%) which was sugges‐
tive of an underlying alpha‐thalassemia. As the seven most common 
alpha deletions were excluded by multiplex gap‐PCR, we decided 
to perform alpha‐globin gene sequencing and we discovered a 
heterozygous Hb Adana variant in the alpha 2‐globin gene (HbA2: 
c.179G>A p.Gly60Asp).To our knowledge, this is the first report of a 
double heterozygote HbE/Hb Adana. The point mutation causative 
of Hb Adana has been reported in the literature occurring on the 
alpha 1‐ and alpha 2‐globin genes (codon 59 GGC → GAC). The mu‐
tation results in a Gly → Asp substitution in the alpha‐globin chain 
of Hb Adana.3 This amino acid substitution replaces a small non‐
charged glycine with a large charged aspartic acid molecule, which 
compromises alpha‐globin chain stability and leads to abnormal pre‐
cipitation and red cell membrane damage, hemolysis, and ineffective 
erythropoiesis.4 Especially when on the dominantly expressed alpha 
2‐globin gene, this mutation may even cause HbH hydrops fetalis in 
homozygosity or in combination with alpha 0‐thalassemia.2,5
Due to its unstable nature, heterozygosity for Hb Adana is not 
visible by routine biochemical assay such as HPLC and CE,6 but the 
carrier does present with microcytic hypochromic parameters. As 
carriers of HbE may also present with mild microcytic hypochromic 
parameters, the co‐inheritance of alpha‐thalassemia defects could 
be easily overlooked unless the HbE percentage is taken into ac‐
count, which is usually slightly decreased in those cases. In our case, 
the decrease in percentage of HbE was only visible on CE, while 
the hematology (normal MCV) and the percentage of HbE on HPLC 
Parameters Patient results
Normal reference 
range
Reference range for HbE 
carriers in our department
Hb (g/dL) 14.1 M: 13.0‐18.0 11.3‐14.3
MCV (fL) 83.0 80.0‐96.0 73.0‐86.0
MCH (pg) 25.1 27.4‐33.8 23.0‐32.0
ZPP (μmol/
mol heme)
47.0 <100.0 <100.0
CE
 HbA (%) 76.0 96.8‐97.8 ‐
 HbA2 (%) 3.0 2.2‐3.2 ‐
 HbF (%) 0.0 0.0 ‐
 HbE (%) 20.2 0.0 23.3–26.2
HPLC
 HbA(%) 59.1 >80.0 ‐
 HbA2(%) 3.7 2.3‐3.3 ‐
 HbF(%) 0.2 0.0 ‐
 HbE(%) 25.8 0.0 23.4–28.4
β‐sequencing het. HBB:c.79G>A 
(p.Glu27Lys)(HbE)
α2‐sequencing het. HBA2:c.179G>A 
(p.Gly60Asp)
CE, capillary electrophoresis; Hb, hemoglobin; HPLC, high‐performance liquid chromatography; 
MCH, mean corpuscular Hb; MCV, mean corpuscular volume; ZPP, zinc protoporphyrin; α2‐sequenc‐
ing, alpha 2‐globin gene sequencing; β‐sequencing, beta globin gene sequencing.
TA B L E  1   Hematological, biochemical, 
and DNA results of our patient
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(25.8%) were not suggestive of an additional alpha‐globin defect 
(Table 1).
A complicating feature in the quantification of the HbE fraction 
may be the overestimation of HbE due to the inability to separate 
it from HbA2 by many HPLC systems presently used for hemoglob‐
inopathy diagnostics.7 The Premier High Resolution (Trinity Biotech) 
HPLC system used is capable of separating HbE from HbA2; how‐
ever, as shown in Figure 1, the separation between HbA2 and HbE is 
better in CE, which explains why the HPLC measurement of the HbE 
is within the normal range of the HbE carrier without alpha‐thalas‐
semia. Therefore, borderline low HbE levels and low MCV and MCH 
should not be ignored and should be investigated for co‐inherited 
alpha‐thalassemia defects.
The identification of a highly unstable alpha‐globin variants such 
as Hb Adana has genetic implications for counseling to prevent a 
severe form of alpha‐thalassemia such as a HbH—hydrops fetalis. A 
recent literature study revealed that cases of Hb Adana associated 
with hydrops fetalis did not follow the classical alpha‐thalassemia 
paradigm where four alpha‐globin gene deletions are typically causal 
of Hb Bart's hydrops fetalis syndrome. If the partner is a carrier of 
Hb Adana on the alpha 2‐globin gene as well or is carrier of SEA, in 
which alleles are particularly frequent in the Indonesian population 
(16% and 4%‐14%, respectively), there is a 25% risk of having a HbH 
hydrops fetalis in the offspring.2,5,8 In addition, the alpha 2‐globin 
variant (c.179G>A) found in our patient has been more associated, 
in the literature, with severe phenotypes in homozygous or in com‐
pound heterozygous states than alpha 1‐globin gene Hb Adana mu‐
tation 2,9‐11 which underlines the importance to determine the exact 
genotype of these variants in carriers.
In conclusion, our case confirms that hematologists evaluating 
patients with anemia should perform a thorough evaluation for alpha‐
thalassemia, which, besides the commonly used gap‐PCR for the 
seven most common deletions, should also include alpha‐globin gene 
sequencing. Careful evaluation of both hematological, biochemical 
separation, and DNA analysis is essential to diagnosis all combinations 
of beta and alpha‐globin gene defects in order to determine precise 
genetic risk in the carriers to provide adequate genetic counseling.12
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